Zentiva Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Zentiva's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2018 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Zentiva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 18 | 36 | 2 | 12 | 0 |
| 31 Dec 17 | 143 | 78 | 14 | 0 |
| 31 Dec 16 | 83 | 17 | 27 | 0 |
| 31 Dec 15 | 113 | 18 | 29 | 0 |
| 31 Dec 14 | 140 | 40 | 34 | 0 |
| 31 Dec 13 | 166 | 52 | 36 | 0 |
Quality Earnings: Insufficient data to determine if 1SKF401E has high quality earnings.
Growing Profit Margin: Insufficient data to determine if 1SKF401E's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1SKF401E's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 1SKF401E's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if 1SKF401E's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: 1SKF401E has a negative Return on Equity (0%), as it is currently unprofitable.